Company: NIVFW
Filing Date: 2025-08-21
Form Type: DRS
Source: 0001213900-25-079301
Chunk: 131

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-21
Form: DRS
Chunk 131
---
 year depending on the results of the financial year of the company.

<div align='center'>75</div>

Quantitative and Qualitative Disclosure about Market Risk

Accounts receivable

In order to minimize the credit
risk, NewGenIvf’s management team monitors and ensures that follow-up action is taken to recover overdue debts. NewGenIvf considers
the probability of default upon initial recognition of the asset and whether there has been a significant increase in credit risk on an
ongoing basis throughout each reporting period. To assess whether there is a significant increase in credit risk, NewGenIvf compares the
risk of a default occurring on the asset as at the reporting date with the risk of default as at the date of initial recognition. It considers
available reasonable and supportive forwarding-looking information, such as GDP growth rate and nominal GDP per capita. Based on the impairment
assessment performed by NewGenIvf, the directors considered the loss allowance for account receivables as of December 31, 2023 and
December 31, 2024 is $19 and $19, respectively.

Cash and cash equivalents

NewGenIvf is exposed to concentration
of credit risk on liquid funds which are deposited with several banks with high credit ratings. The credit risk on liquid funds is limited
because the counterparties are banks with high credit ratings assigned by international credit-rating agencies.

Deposits and other receivables, amount due from shareholders and loan to A SPAC I

NewGenIvf assessed the impairment
for deposits and other receivables, due from shareholders and loan to A SPAC I individually based on internal credit rating and ageing
of these debtors which, in the opinion of the directors, have no significant increase in credit risk since initial recognition. Based
on the impairment assessment performed by the Company, the directors consider the loss allowance for deposits and other receivables and
due from shareholders as of December 31, 2024 was US$4 and Nil respectively. The loss allowance for deposits and other receivables, and
due from shareholders and loan to A SPAC I as of December 31, 2023 is $14, $17,818 and Nil, respectively.

Cash flow interest rate risk

NewGenIvf is exposed to cash
flow interest rate risk through the changes in interest rates related mainly to its variable-rates bank balances.

NewGenIvf currently does not
have any interest rate hedging policy in relation to fair value interest rate risk and cash flow interest